BRIEF—More launches for Humira biosimilar Hukyndra

Icelandic firm Alvotech and Germany’s STADA Arzneimittel are launching their Humira (adalimumab) biosimilar Hukyndra in several European countries.

STADA received approval in Europe in November 2021, and in June 2022 started its regional launch with larger markets in France, Germany, Finland, and Sweden.

The biosimilar to AbbVie’s immunosuppressant - a mega-blockbuster facing a series of patent expiries in coming periods - will now be available in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia.

In November 2019, STADA and Alvotech announced an exclusive partnership covering biosimilar candidates across immunology, oncology and ophthalmology indications.

As part of the firms’ collaboration, Alvotech is supplying Hukyndra autoinjectors and pre-filled syringes with drug product and drug substance, manufactured in Reykjavik.